These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 24484574)
1. Management of urinary tract infections from multidrug-resistant organisms. Gupta K; Bhadelia N Infect Dis Clin North Am; 2014 Mar; 28(1):49-59. PubMed ID: 24484574 [TBL] [Abstract][Full Text] [Related]
2. Advantage and limitations of nitrofurantoin in multi-drug resistant Indian scenario. Shakti L; Veeraraghavan B Indian J Med Microbiol; 2015; 33(4):477-81. PubMed ID: 26470951 [TBL] [Abstract][Full Text] [Related]
3. Treatment of lower urinary tract infection caused by multidrug-resistant extended-spectrum-beta-lactamase-producing Escherichia coli with amoxicillin/clavulanate: case report and characterization of the isolate. Lagacé-Wiens PR; Nichol KA; Nicolle LE; DeCorby M; McCracken M; Mulvey MR; Zhanel GG J Antimicrob Chemother; 2006 Jun; 57(6):1262-3. PubMed ID: 16565157 [No Abstract] [Full Text] [Related]
4. Clinical Management of an Increasing Threat: Outpatient Urinary Tract Infections Due to Multidrug-Resistant Uropathogens. Walker E; Lyman A; Gupta K; Mahoney MV; Snyder GM; Hirsch EB Clin Infect Dis; 2016 Oct; 63(7):960-5. PubMed ID: 27313263 [TBL] [Abstract][Full Text] [Related]
5. [ESBL--increasing resistance problems. Cephalosporins no longer obvious choice in diffuse infections]. Hallgren H; Gustafsson I; Ripa T Lakartidningen; 2007 Dec; 104(51-52):3883-5. PubMed ID: 18232531 [No Abstract] [Full Text] [Related]
7. Predicting Antibiotic Resistance in Urinary Tract Infection Patients with Prior Urine Cultures. Dickstein Y; Geffen Y; Andreassen S; Leibovici L; Paul M Antimicrob Agents Chemother; 2016 Aug; 60(8):4717-21. PubMed ID: 27216064 [TBL] [Abstract][Full Text] [Related]
8. What about Urinary Tract Infections and its Antibiotic Resistance Bacteria in Ilam, Iran? Esmaili K; Mohebi R; Sadeghifard N; Taherikalani M; Pakzad I; Maleki A; Valadbeigi H; Ghafourian S Infect Disord Drug Targets; 2018; 18(3):214-217. PubMed ID: 29932037 [TBL] [Abstract][Full Text] [Related]
9. Antimicrobial resistance patterns of uropathogens among children in Istanbul, Turkey. Ipek IO; Bozaykut A; Arman DC; Sezer RG Southeast Asian J Trop Med Public Health; 2011 Mar; 42(2):355-62. PubMed ID: 21710858 [TBL] [Abstract][Full Text] [Related]
10. Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Lampri N; Galani I; Poulakou G; Katsarolis I; Petrikkos G; Giamarellou H; Souli M J Antimicrob Chemother; 2012 Oct; 67(10):2424-8. PubMed ID: 22665388 [TBL] [Abstract][Full Text] [Related]
11. Outcome of urinary tract infections caused by extended spectrum β-lactamase-producing Enterobacteriaceae in children. Tratselas A; Iosifidis E; Ioannidou M; Saoulidis S; Kollios K; Antachopoulos C; Sofianou D; Roilides EJ Pediatr Infect Dis J; 2011 Aug; 30(8):707-10. PubMed ID: 21248655 [TBL] [Abstract][Full Text] [Related]
12. Transferable drug resistance (R-factor) among the enterobacteriaceae in urinary tract infections: a study at an urban hospital in Bangladesh. Chowdhury MA; Rahman KM; Miah MR; Haq JA J Trop Med Hyg; 1994 Jun; 97(3):161-6. PubMed ID: 8007056 [TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of guidelines and therapeutic approaches in multi drug-resistant urinary tract infections. Concia E; Bragantini D; Mazzaferri F J Chemother; 2017 Dec; 29(sup1):19-28. PubMed ID: 29271735 [TBL] [Abstract][Full Text] [Related]
14. Pathogen occurrence and antimicrobial susceptibility of urinary tract infection cases during a 20-year period (1983-2002) at a single institution in Japan. Shigemura K; Tanaka K; Okada H; Nakano Y; Kinoshita S; Gotoh A; Arakawa S; Fujisawa M Jpn J Infect Dis; 2005 Oct; 58(5):303-8. PubMed ID: 16249626 [TBL] [Abstract][Full Text] [Related]
15. [Antibiotic resistance among E. coli isolates from urinary tract infections (1999-2000): a multicenter study]. Smaoui H; Mahjoubi F; Boutiba I; Jouaihia W; Thabet L; Znazen A; Kammoun A; Mezghanni S; Triki O; Hammami A; Ben Hassen A; Kechrid A; Ben Redjeb S Tunis Med; 2003 Jun; 81(6):390-4. PubMed ID: 14534944 [TBL] [Abstract][Full Text] [Related]
16. Multi-drug resistance of Escherichia coli from the urinary tract. Rafay AM; Nsanze HN Saudi Med J; 2003 Mar; 24(3):261-4. PubMed ID: 12704500 [TBL] [Abstract][Full Text] [Related]
17. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. Arslan H; Azap OK; Ergönül O; Timurkaynak F; J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685 [TBL] [Abstract][Full Text] [Related]
18. Potential role of fosfomycin in the treatment of community-acquired lower urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Wilson DT; May DB Am J Ther; 2013; 20(6):685-90. PubMed ID: 21768870 [TBL] [Abstract][Full Text] [Related]
19. Emerging resistance problems and future perspectives in pharmacotherapy for complicated urinary tract infections. Chen YH; Ko WC; Hsueh PR Expert Opin Pharmacother; 2013 Apr; 14(5):587-96. PubMed ID: 23480061 [TBL] [Abstract][Full Text] [Related]
20. Bacterial characteristics of importance for recurrent urinary tract infections caused by Escherichia coli. Ejrnæs K Dan Med Bull; 2011 Apr; 58(4):B4187. PubMed ID: 21466767 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]